Wegovy is a registered trademark of Novo Nordisk A/S. It is an FDA-approved prescription medicine that contains semaglutide, a glucagon-like peptide-1 receptor agonist. It is available in prescription injection and tablet forms for specific labeled uses.
Important safety information: Wegovy has a boxed warning for the risk of thyroid C-cell tumors. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma, known as MTC, or Multiple Endocrine Neoplasia syndrome type 2, known as MEN 2. Major serious risks include pancreatitis, gallbladder disease, low blood sugar with certain diabetes medicines, kidney injury due to dehydration, severe stomach problems, serious allergic reactions, diabetic retinopathy complications, increased heart rate, and pulmonary aspiration during anesthesia or deep sedation. Common side effects include nausea, diarrhea, vomiting, constipation, and stomach pain. Read the full official Prescribing Information and Medication Guide. A licensed clinician should consider the potential benefits and risks for each patient.
It is not a supplement or an over-the-counter product. It requires a prescription, and suitability cannot be determined from a general article or body mass index alone.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
What semaglutide does
Semaglutide acts on the GLP-1 receptor. The current prescribing information explains that GLP-1 helps regulate appetite and calorie intake. The medicine also slows stomach emptying, which can affect how some oral medicines are absorbed.
Those effects are why a clinician needs a complete medication list, health history, and clear treatment goal. The clinician may need to consider diabetes medicines, digestive conditions, kidney concerns, eye disease related to diabetes, planned surgery, pregnancy, and other factors before prescribing.
The product should not be used at the same time as another semaglutide-containing product or another GLP-1 receptor agonist. A patient should not combine, switch, stop, or change doses without instructions from the prescribing clinician.
What it is approved to do
The official prescribing information lists several specific uses. Injection and tablet forms are indicated, with a reduced-calorie diet and increased physical activity, for long-term weight reduction in certain adults. The injection also has a pediatric weight-management indication for certain patients age 12 and older.
Both forms are indicated to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. The injection labeling also includes treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults. That liver indication uses accelerated approval and has specific labeling conditions.
These are descriptions of FDA-approved uses, not a recommendation for any reader. Each indication has detailed criteria, and not every form has every use. A clinician must match the person's situation to the current label.
Injection and tablet forms are not casual substitutes
The injection is administered under the skin according to a gradual dosing schedule. Depending on the presentation, the patient may receive a single-dose device or a multi-dose device. Training should match the exact product dispensed.
The tablet is taken by mouth under specific fasting and water instructions. Its dose schedule and administration directions differ from the injection. The prescribing information also gives instructions for switching between forms.
These differences matter. A person should check the pharmacy label and patient instructions every time the presentation changes. If the package, device, tablet strength, or directions are unexpected, pause and contact the pharmacist or clinician before taking it.
Why the boxed warning matters
In rodent studies, semaglutide caused thyroid C-cell tumors. It is unknown whether it causes these tumors, including MTC, in humans. That uncertainty and the serious nature of the potential harm are reflected in the boxed warning.
A person should tell the clinician about any personal or family history of MTC or MEN 2. The medication is contraindicated in those situations. The labeling also tells patients to report possible thyroid tumor symptoms, such as a neck mass, trouble swallowing, shortness of breath, or ongoing hoarseness.
Seek prompt medical guidance for serious or persistent symptoms. Severe abdominal pain may be a sign of pancreatitis. Ongoing vomiting or diarrhea can cause dehydration and kidney problems. Signs of a severe allergic reaction require emergency help. Patients should tell procedural teams about use before anesthesia or deep sedation because delayed stomach emptying may raise aspiration risk.
What a clinical evaluation covers
A licensed clinician reviews medical conditions, prior reactions, current prescriptions, over-the-counter medicines, and supplements. The clinician may ask about pregnancy plans, blood sugar treatment, digestive symptoms, kidney health, diabetic eye disease, and upcoming procedures.
Laboratory testing may be considered based on the person's history. Follow-up matters because tolerability, symptoms, dose decisions, and the continued balance of risk and benefit can change over time.
A prescription is not guaranteed. The evaluation can result in a different care plan or a decision that medication is not appropriate.
Body Good's role and fees
Body Good provides clinical and administrative services through its program. This can include evaluation by a licensed clinician, follow-up care, coverage support, and pharmacy routing if a prescription is written.
Body Good's $139 per month price is a Body Good service fee for the program described during intake. It is not the price of medication and is not a quote for any individual. Eligibility is determined by a clinician. Medication cost is separate and not included. A pharmacy or another authorized provider charges for any medication dispensed.
Coverage support may include a benefits check and help with paperwork. The health plan determines approval and payment. Body Good cannot guarantee a prescription, coverage, a pharmacy price, or a clinical outcome.
This website is an informational and pricing overview. It takes no payment, collects no protected health information, and runs no intake form. All intake and checkout occur on joinbodygood.com.
Frequently asked questions
Is Wegovy insulin?
No. It contains semaglutide, a GLP-1 receptor agonist. It is not insulin. People who use insulin or certain other diabetes medicines should discuss the risk of low blood sugar with a clinician.
Is a tablet the same to use as an injection?
No. The forms have different administration and dosing instructions, and some labeled uses differ. Follow the directions for the exact prescription and do not switch forms on your own.
How can I ask whether it may fit my situation?
A licensed clinician must review your history, medicines, goals, and risks. Begin Body Good's secure clinical intake to provide information for an individualized review.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.